Patents Represented by Attorney, Agent or Law Firm Karen L. Prus
-
Patent number: 6332897Abstract: The present invention relates to an automated format for the yeast two hybrid assay for protein-protein interactions.Type: GrantFiled: March 27, 1998Date of Patent: December 25, 2001Assignee: Glaxo Wellcome Inc.Inventors: Michael Phillip Weiner, Richard Gordon Buckholz
-
Patent number: 6281367Abstract: An improved process for the synthesis of (3S)-tetrahydro-3-furyl N-[(1S,2R)-3 -(4-amino-N-isobutylbenzenesulphonamido)-1-benzyl-2-hydroxypropyl]carbamate comprising four steps form the compound of formula A and a novel intermediate thereto.Type: GrantFiled: December 12, 2000Date of Patent: August 28, 2001Assignee: Glaxo Wellcome Inc.Inventors: Emile Al-Farhan, David D. Deininger, Stephen McGhie, John O'Callaghan, Mark Stuart Robertson, Keith Rodgers, Stephen John Rout, Hardew Singh, Roger Dennis Tung
-
Patent number: 6147254Abstract: A process for the preparation of carbocyclic stereoisomers of formulae (I), (I'), (IIA'), (IIB'), (VA') and (VB'), including enantiomerically pure (IIA'), (I) and (I') utilizing fractional crystallization of salts formed with a chiral base; a reducing agent; a protecting group removing agent or a protecting group providing agent.Type: GrantFiled: August 6, 1999Date of Patent: November 14, 2000Assignee: Glaxo Wellcome Inc.Inventors: Barry Riddle Sickles, Kenneth James Ingold, Christopher John Wallis
-
Patent number: 6113920Abstract: A pharmaceutical composition and a method of inhibiting human immunodeficiency virus (HIV) is disclosed which comprises administering to an HIV infected patient a homogenous combination of lamivudine, zidovudine and a pharmaceutical glidant in an amount which achieves antiviral efficacy.Type: GrantFiled: October 23, 1997Date of Patent: September 5, 2000Assignee: Glaxo Wellcome Inc.Inventors: Katherine Jeannette Maye, Gary Wayne Goodson, Allen Wayne Wood
-
Patent number: 6107288Abstract: Synergistic combinations of nucleoside derivatives, pharmaceutical formulations containing said combinations and use of the combinations in the treatment of retroviral infections are disclosed.Type: GrantFiled: April 27, 1993Date of Patent: August 22, 2000Inventors: Phillip Allen Furman, Jr., George Robert Painter, III
-
Patent number: 6087501Abstract: A process for the preparation of a compound of formula (III) ##STR1## by hydrolyzing a compound of formula (I) or (II) ##STR2## wherein R.sup.1 and R.sup.2, which may be the same or different, are selected from C.sub.1-8 alkyl, C.sub.3-8 cycloalkyl, and optionally substituted aryl, in the presence of acid at a pH above 2.0.Type: GrantFiled: October 24, 1997Date of Patent: July 11, 2000Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Michael Tolar Martin
-
Patent number: 6004968Abstract: The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.Type: GrantFiled: March 20, 1998Date of Patent: December 21, 1999Assignee: Glaxo Wellcome Inc.Inventors: Warren Michael Casey, Ngoc-Anh Thi Nguyen
-
Patent number: 5919941Abstract: The present invention relates to intermediates for the preparation of sulphonic acid salts of 4-amino-2-cyclopentane-1-carboxylic acid.Type: GrantFiled: November 7, 1997Date of Patent: July 6, 1999Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Douglas Alan Livingston
-
Patent number: 5917041Abstract: The present invention is related to a process of making of 2,6-diaminopurines wherein the 6-amino group is substituted by R.sup.4 and R.sup.5, by reacting a compound of formula (VI) ##STR1## with an excess of amine NHR.sup.4 R.sup.5.Type: GrantFiled: October 24, 1997Date of Patent: June 29, 1999Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Michael Tolar Martin
-
Patent number: 5917042Abstract: The present invention relates to a process for the preparation of 2,5-diamino-4,6-dichloropyrimidine.Type: GrantFiled: October 24, 1997Date of Patent: June 29, 1999Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Michael Tolar Martin
-
Patent number: 5885957Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: June 26, 1997Date of Patent: March 23, 1999Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5877163Abstract: A method of treating AIDS with 3'-azido-3'-deoxythymidine in combination with interleukin II or phosphonoformate is presented.Type: GrantFiled: July 10, 1997Date of Patent: March 2, 1999Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5840990Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring ill place of trip sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for there preparation, pharmaceutical formulations containing them, and to the use of such compounds in therapy, particularly the treatment of or prophylaxis of certain viral infections.Type: GrantFiled: November 6, 1996Date of Patent: November 24, 1998Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Douglas Alan Livingston
-
Patent number: 5821236Abstract: 6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.Type: GrantFiled: May 24, 1995Date of Patent: October 13, 1998Assignee: Glaxo Wellcome Inc.Inventors: Thomas Anthony Krenitsky, Devron Randolph Averett, George Walter Koszalka
-
Patent number: 5808147Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain viral infections.Type: GrantFiled: November 7, 1997Date of Patent: September 15, 1998Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Douglas Alan Livingston
-
Patent number: 5747472Abstract: 6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumour therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.Type: GrantFiled: May 31, 1995Date of Patent: May 5, 1998Assignee: Glaxo Wellcome Inc.Inventors: Thomas Anthony Krenitsky, Devron Randolph Averett, George Walter Koszalka, Gerald Wolberg
-
Patent number: 5683990Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir and AZT and 2-amino-9-(2-hydroxyethoxymethyl)purine or an ester thereof.Type: GrantFiled: August 21, 1986Date of Patent: November 4, 1997Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5663154Abstract: 2',3'-Dideoxy-3'-fluoro-(B-D-ribofuranosyl) purine nucleosides possessing the ability to inhibit hepatitis B and HIV viral infections.Type: GrantFiled: June 30, 1994Date of Patent: September 2, 1997Assignee: Glaxo Wellcome Inc.Inventors: Charlene Louise Burns, George Walter Koszalka, Thomas Anthony Krenitsky
-
Patent number: 5643891Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: February 26, 1993Date of Patent: July 1, 1997Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5641889Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain vital infections.Type: GrantFiled: September 12, 1994Date of Patent: June 24, 1997Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Douglas Alan Livingston